Altamira Therapeutics Ltd. (NASDAQ:CYTO – Free Report) – Research analysts at Diamond Equity lifted their FY2024 earnings estimates for shares of Altamira Therapeutics in a research report issued on Wednesday, September 25th. Diamond Equity analyst H. Diamond now anticipates that the company will earn ($2.65) per share for the year, up from their previous estimate of ($4.26). The consensus estimate for Altamira Therapeutics’ current full-year earnings is ($4.26) per share. Diamond Equity also issued estimates for Altamira Therapeutics’ FY2025 earnings at ($1.17) EPS.
Altamira Therapeutics Trading Up 3.1 %
Shares of CYTO stock opened at $0.63 on Monday. The company has a 50 day moving average price of $0.91 and a 200-day moving average price of $1.31. Altamira Therapeutics has a 52 week low of $0.60 and a 52 week high of $17.20.
Altamira Therapeutics Company Profile
Altamira Therapeutics Ltd. operates as a preclinical-stage biopharmaceutical company in Switzerland and Australia. The company develops and supplies OligoPhore/SemaPhore platforms, which are peptide-based nanoparticle technologies for ribonucleic acid delivery to extrahepatic tissues. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.
Further Reading
- Five stocks we like better than Altamira Therapeutics
- Airline Stocks – Top Airline Stocks to Buy Now
- Why Lennar Stock Could Be the Best Play in the Housing Market
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- 2 Energy Stocks Fueling the AI Datacenter Boom
- What is the Dogs of the Dow Strategy? Overview and Examples
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Altamira Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Altamira Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
